People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Healthtech, Biotechnology, Pharmaceuticals, Medical Devices, Energy, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genome Medical Holding Co | — | Healthtech | Series C | $90.0M | $605.8M | 2018 |
| Liquidia Technologies Inc | — | Biotechnology | Series B | $86.7M | $890.0M | 2009 |
| EvolveImmune Therapeutics Holding Company, LLC | — | Biotechnology | Series B | $85.8M | $124.8M | 2020 |
| Marinus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.4M | $21.0M | 2009 |
| Onkos Surgical, Inc. | — | Medical Devices | Series B | $72.3M | $595.1M | 2017 |
| Iantrek, Inc. | — | Biotechnology | Series B | $58.2M | $152.2M | 2020 |
| Dicom Grid Inc | — | Energy | Series A | $44.5M | $78.2M | 2010 |
| Corvium, Inc. | — | Other | Series A | $38.4M | $30.1M | 2016 |
| Viacor Inc | — | Other Health Care | Series A | $33.9M | $38.8M | 2009 |
| Liquidia Corp | — | Biotechnology | Series B | $21.7M | $616.1M | 2021 |
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2015 |
| Allyx Therapeutics, Inc. | — | Biotechnology | Series A | $13.2M | $7.9M | 2021 |
| Axial Exchange, Inc. | — | Other Technology | Series A | $12.8M | $21.6M | 2011 |
| LQ3 Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $4.4M | $89.5M | 2014 |
| Thyron Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $500K | $8.2M | 2022 |
Stephen Bloch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Bloch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Rudnick | 3 | 5 |
| Neal Fowler | 3 | 4 |
| Ed Mathers | 2 | 11 |
| Paul Fonteyne | 2 | 5 |
| Arthur A. Kirsch | 2 | 2 |
| Ryan Drant | 1 | 24 |
| Adele Oliva | 1 | 9 |
| Isaac Cheng | 1 | 9 |
| Robert Green | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| Jon Karlen | 1 | 7 |
| Jeffrey Bussgang | 1 | 7 |
| David B. Johnson | 1 | 6 |
| Christopher M. Cashman | 1 | 6 |
| Myles Greenberg | 1 | 6 |
| David Scheer | 1 | 6 |
| Paul B. Manning | 1 | 6 |
| Adrienne Graves | 1 | 6 |
| Harry H Penner, Jr. | 1 | 6 |
| Micah Rosenbloom | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.